{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":3,"sponsored":0,"items":[{"id":"n_w7ze7jwho3o2bwraz6yq","seq":615584,"kind":"article","title":"2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma","url":"https://www.prnewswire.com/news-releases/2026-ims-oral-presentation-innovent-announces-updated-phase-1-clinical-data-of-trispecific-antibody-ibi3003-gprc5dbcmacd3-in-patients-with-relapsed-or-refractory-multiple-myeloma-302892611.html","published":"2026-09-29T08:15:00Z","seen":"2026-09-29T08:15:20Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","education"],"authors":["Innovent Biologics"],"entities":[{"id":"Q30296199","name":"Innovent","type":"org"}],"story":"st_w7ze7jwho3o2bwraz6yq","category":"health","category_p":0.53,"category2":"science-technology","sentiment":"neutral","tone":0.02,"political":0.04},{"id":"n_aygcky4snstfjhyrakdq","seq":408616,"kind":"article","title":"Innovent's Jaypirca Gets Expanded NMPA Approval For CLL/SLL","url":"https://www.rttnews.com/3694273/innovent-s-jaypirca-gets-expanded-nmpa-approval-for-cll-sll.aspx","published":"2026-09-28T10:39:00Z","seen":"2026-09-28T11:11:39Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["business","economy","health"],"entities":[{"id":"Q30296199","name":"Innovent","type":"org"},{"id":"Q116622551","name":"pirtobrutinib","type":"other"},{"id":"Q17091299","name":"National Music Publishers' Association","type":"org"},{"id":"Q18557229","name":"chronic lymphocytic leukemia and small lymphocytic lymphoma","type":"other"}],"story":"st_aygcky4snstfjhyrakdq","category":"science-technology","category_p":0.44,"category2":"economy-business","sentiment":"positive","tone":0.21,"political":0.05},{"id":"n_eu4nntpuwrkm5tuo47aa","seq":502059,"kind":"article","title":"Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC","url":"https://www.rdrnews.com/online_features/press_releases/innovent-announces-expansion-of-global-phase-3-marslight-11-study-of-ibi363-tak-928-alpha/article_c4caf8c3-39c5-567d-b0c9-9621f98696ee.html","summary":"SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic…","published":"2026-09-28T00:00:00Z","seen":"2026-09-28T19:01:26Z","lang":"en","country":"US","source":{"id":"kite-rdrnews-com-059ec0","name":"rdrnews.com","domain":"rdrnews.com","outlet":{"wikidata":"Q7370099","name":"Roswell Daily Record","type":"newspaper","country":"US","designations":["newspaper"]}},"via":"kite-rdrnews-com-059ec0","topics":["new-mexico"],"authors":["By Innovent Biologics"],"entities":[{"id":"Q30296199","name":"Innovent","type":"org"},{"id":"Q3658562","name":"non-small-cell lung carcinoma","type":"other"}],"story":"st_eu4nntpuwrkm5tuo47aa","category":"science-technology","category_p":0.69,"category2":"health","sentiment":"neutral","tone":0.17,"political":0.04}]}